Bristol-Myers Squibb Completes Acquisition of Celgene
Creating a Leading Biopharma Company
Bristol-Myers Squibb Company (NYSE:BMY) has completed its acquisition of Celgene Corporation to create a leading biopharma company well positioned to deliver on its vision of transforming patients’ lives through science. Bristol-Myers Squibb will:
- Build an even stronger commercial presence in its key disease franchises of oncology, hematology, immunology and cardiovascular disease, led by high performing commercial teams;
- Launch exciting new medicines for patients, including five expected near-term opportunities along with the recent launches of INREBIC® (fedratinib) and REBLOZYL® (luspatercept-aamt);
- Advance a significantly enhanced early-stage pipeline; and
- Integrate a broad range of discovery modalities that will further strengthen its pipeline.
The Company’s significant cash flow generation will support debt reduction, strong investment grade credit ratings and future dividend increases. Bristol-Myers Squibb also has significant financial flexibility to enable continued investment in innovation and realize the full potential of the enhanced late- and early-stage pipeline.
“This is an exciting day for Bristol-Myers Squibb as we bring together the leading science, innovative medicines and incredible talent of Bristol-Myers Squibb and Celgene to create a leading biopharma company. With our leading franchises in oncology, hematology, immunology and cardiovascular disease and one of the most diverse and promising pipelines in the industry, I know we will deliver on our vision of transforming patients’ lives through science. I am excited about the opportunities for our current employees and the new colleagues that we welcome to the Company as we work together to deliver innovative medicines to patients.”